Finally, tumor-bearing mice that responded to treatment (long-term survivors) showed statistical increases in IL-1α, IL-15, CXCL5, and IL-12 p40 when compared to tumor-free control mice, indicating a distinctive immune activating systemic cytokine profile ten weeks post 4T1 FUGW-FL tumor implantation (Supplementary Fig. 8f, g). The gene discussed is IL1A; the disease is neoplasm.